Mark Neumann - Aug 16, 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Commercial Officer
Signature
/s/ John P. Condon, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Aug 16, 2024
Transactions value $
-$714,688
Form type
4
Date filed
8/20/2024, 06:03 PM
Previous filing
Mar 11, 2024
Next filing
Feb 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $690K +18.7K +63.01% $36.89 48.4K Aug 16, 2024 Direct F1
transaction ITCI Common Stock Sale -$1.41M -18.7K -38.65% $75.08 29.7K Aug 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -18.7K -100% $0.00 0 Aug 16, 2024 Common Stock 18.7K $36.89 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 16, 2024, the reporting person exercised options to purchase 18,714 shares of common stock.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 All shares underlying this option have vested.

Remarks:

EX-24.1 - Power of Attorney